US2022160690A1PendingUtilityA1

Methods for Treatment of Fabry Disease

82
Assignee: AMICUS THERAPEUTICS INCPriority: May 16, 2006Filed: Feb 7, 2022Published: May 26, 2022
Est. expiryMay 16, 2026(expired)· nominal 20-yr term from priority
Inventors:David J. LockhartJeff Castelli
A61K 31/445A61K 45/06G01N 33/5094A61P 9/00G01N 2800/04A61P 43/00G01N 2333/94G01N 2800/52G01N 2333/924A61K 9/0053A61P 9/10A61K 31/45C07D 211/46A61P 13/12A61K 9/48A61P 3/00
82
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Provided are in vitro and in vivo methods for determining whether a patient with Fabry disease will respond to treatment with a specific pharmacological chaperone.

Claims

exact text as granted — not AI-modified
1 - 34 . (canceled) 
     
     
         35 . A method for treatment of Fabry disease in a human patient in need thereof, the method comprising administering to the patient a therapeutically effective dose of 1-deoxygalactonojirimycin or a salt thereof every other day.

Join the waitlist — get patent alerts

Track US2022160690A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.